BrainCool AB (SE:BRAIN)
:BRAIN
Want to see SE:BRAIN full AI Analyst Report?
BRAIN Stock Chart & Stats
kr0.58
kr0.19(9.74%)
At close: 4:00 PM EST
kr0.58
kr0.19(9.74%)
Day’s Range― - ―
52-Week Rangekr0.41 - kr1.84
Previous CloseN/A
Volume974.66K
Average Volume (3M)201.46K
Market Cap
kr319.85M
Enterprise Valuekr165.89M
Total Cash (Recent Filing)kr39.57M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta0.24
Next Earnings
Jun 03, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding394,878,140
10 Day Avg. Volume223,544
30 Day Avg. Volume201,464
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)0.85
Price to Sales (P/S)4.14
P/FCF Ratio-2.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.06
Revenue Forecast (FY)kr72.00M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetZero reported debt across 2022–2025 gives BrainCool durable financial flexibility. Without interest burden the company can prioritize R&D, commercialization and clinical rollout funding from available equity and cash, reducing near-term default risk and enabling strategic choices.
Rising Equity And Asset BaseIncreasing equity and total assets expand the company’s capital base, supporting multi-year investments in sales, clinical studies and product development. A larger asset/equity cushion improves solvency and provides room to absorb operating losses while pursuing commercialization.
Multi-year Revenue Scale-upFive-year revenue expansion suggests product adoption and commercial traction in core markets. That historical growth supports the installed-base economics needed for recurring consumable and service revenue, which can underpin longer-term margin improvement if unit economics are fixed.
Bears Say
Persistent Negative Free Cash FlowSustained negative operating and free cash flow indicates real cash burn rather than accounting items. Continued outflows will force external financing or equity raises, constraining strategic options, increasing dilution risk and limiting ability to self-fund commercialization over the medium term.
Negative Gross Profit In Latest YearA negative gross profit in 2025 signals core product economics are currently unfavorable. Without improvements to pricing, manufacturing costs, or product mix, revenue growth will not translate into sustainable profits, pressuring margins and long-term viability of operations.
Uneven Recent Revenue TrajectoryA 17% revenue decline in 2025 after prior growth highlights execution and adoption risk. Dependence on hospital adoption, reimbursement and distributor performance makes top-line volatile, complicating forecasting and the buildup of stable recurring consumable/service revenue streams.
BrainCool AB News
BRAIN FAQ
What was BrainCool AB’s price range in the past 12 months?
BrainCool AB lowest stock price was kr0.41 and its highest was kr1.84 in the past 12 months.
What is BrainCool AB’s market cap?
BrainCool AB’s market cap is kr319.85M.
When is BrainCool AB’s upcoming earnings report date?
BrainCool AB’s upcoming earnings report date is Jun 03, 2026 which is in 33 days.
How were BrainCool AB’s earnings last quarter?
BrainCool AB released its earnings results on Feb 11, 2026. The company reported kr0 earnings per share for the quarter, the consensus estimate of kr0 by kr0.
Is BrainCool AB overvalued?
According to Wall Street analysts BrainCool AB’s price is currently Overvalued.
Does BrainCool AB pay dividends?
BrainCool AB does not currently pay dividends.
What is BrainCool AB’s EPS estimate?
BrainCool AB’s EPS estimate is 0.
How many shares outstanding does BrainCool AB have?
BrainCool AB has 394,878,140 shares outstanding.
What happened to BrainCool AB’s price movement after its last earnings report?
BrainCool AB reported an EPS of kr0 in its last earnings report, expectations of kr0. Following the earnings report the stock price went down -3.2%.
Which hedge fund is a major shareholder of BrainCool AB?
Currently, no hedge funds are holding shares in SE:BRAIN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BrainCool AB
BrainCool AB (publ), a medical device company, together with its subsidiaries, engages in the development, marketing, and sale of medical cooling systems for the healthcare sector in Sweden. The company offers products for medical cooling treatments for a range of diseases, including stroke, sudden cardiac arrest, oral mucositis, and migraine. It provides BrainCool and RhinoChill systems that facilitates rapid medical cooling treatment in an emergency setting and ensures the continuum of care; Cooral system provides medical professionals an easy way to reduce the risk of oral mucositis; and IQool system offers an easy-to-use intuitive interface, informative graphics, and an automatic feedback loop allowing clinicians to manage their patient rather than a device. The company was incorporated in 2010 and is based in Lund, Sweden.
Technical Analysis
Bactiguard Holding AB
―
C-Rad AB Class B
―
Acarix AB
―
Sedana Medical AB
―
Mentice AB
―